Trials / Withdrawn
WithdrawnNCT02528617
The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Baylor Research Institute · Academic / Other
- Sex
- All
- Age
- 4 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the effect of Velaglucerase Alfa on skeletal bone development of children with Type 1 or Type 3 Gaucher Disease. In addition, the natural history and neurological status of children with Type 3 Gaucher Disease will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Velaglucerase alfa | Enzyme replacement therapy |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2015-08-19
- Last updated
- 2018-03-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02528617. Inclusion in this directory is not an endorsement.